2026 Q2 - tulosraportti
72 päivää sitten
‧1 t 1 min
1,73 USD/osake
Viimeisin osinko
0,53%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·8 t sitten1. Weight loss figures (Who loses the most?) If we compare the two oral medications (oral treatment), the Wegovy pill has shown slightly higher average weight loss figures than Foundayo: • Wegovy pill (25 mg): Provides an average weight loss of approx. 13.6% to 14% of body weight after a solid year (64 weeks). The weekly Wegovy injection can provide up to 15-17% on average. • Foundayo pill (17.2 mg): Provides an average weight loss of approx. 11% to 12.4% of body weight after 72 weeks. 2. Side effects (Which is gentler?) Both preparations are GLP-1-based, which means they have virtually the same types of side effects. The side effects are most pronounced in the initial phase when the dose is escalated, and are typically mild to moderate. The most common gastrointestinal side effects (affecting over 10%): • Nausea • Diarrhea or constipation • Vomiting and stomach pain Which is best regarding side effects? Studies show that the incidence is very similar, but a small difference is seen in how many completely discontinue treatment due to discomfort: • In the studies with the Wegovy pill, 6.9% of participants stopped early due to side effects. • In the studies with Foundayo, 8% of participants stopped early due to side effects. Direct comparison of the two pills Feature Wegovy (oral form) Foundayo (oral form) Average weight loss 13.6% – 14% (Higher efficacy) 11% – 12.4% Gastrointestinal side effects Very common (approx. 74%) Very common (60-69%) Discontinuation due to side effects 6.9% (Slightly fewer) 8% Administration requirements Must be taken on an empty stomach in the morning with at most a small glass of water. Thereafter, you must fast for 30 minutes. Can be taken at any time of day, with or without food and drink (Much more flexible). Summary: What should you choose? • Wegovy is best on the numbers, as it has yielded a slightly greater weight loss in clinical studies. • Foundayo is best on everyday comfort, because you avoid the strict morning fasting rules that the Wegovy pill requires. Note: While Wegovy is widely available, Foundayo (orforglipron) is approved in the US and UK, but is still awaiting final rollout on the Danish market following EU approval. If you are considering medical weight loss, I can help you look into it further. Are you primarily considering pills, or is the Wegovy injection (taken once a week) also an option for you? • Skanfeld Wegovy pill vs Foundayo — which GLP-1 pill? - Skanfeld Sep. 22, 2026 — The Wegovy pill gave on average slightly greater weight loss than Foundayo — and was close to the Wegovy injection. The figures come from various stu... • Pharmica Foundayo vs Wegovy Pill: Dosing and Side Effects Compared Active Ingredients: Foundayo (orforglipron, Eli Lilly); Wegovy pill (oral semaglutide, Novo Nordisk). Licensed Uses: Foundayo (wei... • Oxford Online Pharmacy Wegovy pill vs Foundayo pill (Orforglipron): Which GLP-1 weight loss pill is better? Wegovy pill: Semaglutide, 13-16% body weight loss, strict fasting morning administration required, 4 step-up doses. Foundayo: Orfo... Show all This is for informational purposes only.
·6.10.I uploaded a video about how Eli Lilly dominates so much, and how they have a broad approach to the obesity market + that they are much more than just the obesity company many think they are: Eli Lilly (LLY): The Company That Beat Novo Nordisk (NVO https://youtu.be/HFBz-zoLH5M (Not advice, just my opinion)
- ·1.10.1 Major Novo competitor rejects disappointment Novo's major competitor Eli Lilly rejects disappointment over the weight loss pill Foundayo. This is reported by Finans based on an interview with the chief commercial officer at Eli Lilly, American Kenneth Custer. Sales amounted to 98 million dollars in the second quarter, but that was quite a bit less than investors had hoped for. Kenneth Custer points out that the company already has one third new pill patients with a brand that is only five months old, and which no one knew beforehand. He therefore rejects that Eli Lilly should be disappointed. maybe the downturn is coming now : )))))
29.9.Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more- 29.9.Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss
And even more side effects incl deaths, that is then mentioned in other financial media🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
72 päivää sitten
‧1 t 1 min
1,73 USD/osake
Viimeisin osinko
0,53%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sitten1. Weight loss figures (Who loses the most?) If we compare the two oral medications (oral treatment), the Wegovy pill has shown slightly higher average weight loss figures than Foundayo: • Wegovy pill (25 mg): Provides an average weight loss of approx. 13.6% to 14% of body weight after a solid year (64 weeks). The weekly Wegovy injection can provide up to 15-17% on average. • Foundayo pill (17.2 mg): Provides an average weight loss of approx. 11% to 12.4% of body weight after 72 weeks. 2. Side effects (Which is gentler?) Both preparations are GLP-1-based, which means they have virtually the same types of side effects. The side effects are most pronounced in the initial phase when the dose is escalated, and are typically mild to moderate. The most common gastrointestinal side effects (affecting over 10%): • Nausea • Diarrhea or constipation • Vomiting and stomach pain Which is best regarding side effects? Studies show that the incidence is very similar, but a small difference is seen in how many completely discontinue treatment due to discomfort: • In the studies with the Wegovy pill, 6.9% of participants stopped early due to side effects. • In the studies with Foundayo, 8% of participants stopped early due to side effects. Direct comparison of the two pills Feature Wegovy (oral form) Foundayo (oral form) Average weight loss 13.6% – 14% (Higher efficacy) 11% – 12.4% Gastrointestinal side effects Very common (approx. 74%) Very common (60-69%) Discontinuation due to side effects 6.9% (Slightly fewer) 8% Administration requirements Must be taken on an empty stomach in the morning with at most a small glass of water. Thereafter, you must fast for 30 minutes. Can be taken at any time of day, with or without food and drink (Much more flexible). Summary: What should you choose? • Wegovy is best on the numbers, as it has yielded a slightly greater weight loss in clinical studies. • Foundayo is best on everyday comfort, because you avoid the strict morning fasting rules that the Wegovy pill requires. Note: While Wegovy is widely available, Foundayo (orforglipron) is approved in the US and UK, but is still awaiting final rollout on the Danish market following EU approval. If you are considering medical weight loss, I can help you look into it further. Are you primarily considering pills, or is the Wegovy injection (taken once a week) also an option for you? • Skanfeld Wegovy pill vs Foundayo — which GLP-1 pill? - Skanfeld Sep. 22, 2026 — The Wegovy pill gave on average slightly greater weight loss than Foundayo — and was close to the Wegovy injection. The figures come from various stu... • Pharmica Foundayo vs Wegovy Pill: Dosing and Side Effects Compared Active Ingredients: Foundayo (orforglipron, Eli Lilly); Wegovy pill (oral semaglutide, Novo Nordisk). Licensed Uses: Foundayo (wei... • Oxford Online Pharmacy Wegovy pill vs Foundayo pill (Orforglipron): Which GLP-1 weight loss pill is better? Wegovy pill: Semaglutide, 13-16% body weight loss, strict fasting morning administration required, 4 step-up doses. Foundayo: Orfo... Show all This is for informational purposes only.
- ·6.10.I uploaded a video about how Eli Lilly dominates so much, and how they have a broad approach to the obesity market + that they are much more than just the obesity company many think they are: Eli Lilly (LLY): The Company That Beat Novo Nordisk (NVO https://youtu.be/HFBz-zoLH5M (Not advice, just my opinion)
- ·1.10.1 Major Novo competitor rejects disappointment Novo's major competitor Eli Lilly rejects disappointment over the weight loss pill Foundayo. This is reported by Finans based on an interview with the chief commercial officer at Eli Lilly, American Kenneth Custer. Sales amounted to 98 million dollars in the second quarter, but that was quite a bit less than investors had hoped for. Kenneth Custer points out that the company already has one third new pill patients with a brand that is only five months old, and which no one knew beforehand. He therefore rejects that Eli Lilly should be disappointed. maybe the downturn is coming now : )))))
- 29.9.Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more
- 29.9.Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-lossAnd even more side effects incl deaths, that is then mentioned in other financial media🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
72 päivää sitten
‧1 t 1 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 29.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
Vuosittainen yhtiökokous 2026 4.5. | ||
2026 Q1 - tulosraportti 30.4. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
1,73 USD/osake
Viimeisin osinko
0,53%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·8 t sitten1. Weight loss figures (Who loses the most?) If we compare the two oral medications (oral treatment), the Wegovy pill has shown slightly higher average weight loss figures than Foundayo: • Wegovy pill (25 mg): Provides an average weight loss of approx. 13.6% to 14% of body weight after a solid year (64 weeks). The weekly Wegovy injection can provide up to 15-17% on average. • Foundayo pill (17.2 mg): Provides an average weight loss of approx. 11% to 12.4% of body weight after 72 weeks. 2. Side effects (Which is gentler?) Both preparations are GLP-1-based, which means they have virtually the same types of side effects. The side effects are most pronounced in the initial phase when the dose is escalated, and are typically mild to moderate. The most common gastrointestinal side effects (affecting over 10%): • Nausea • Diarrhea or constipation • Vomiting and stomach pain Which is best regarding side effects? Studies show that the incidence is very similar, but a small difference is seen in how many completely discontinue treatment due to discomfort: • In the studies with the Wegovy pill, 6.9% of participants stopped early due to side effects. • In the studies with Foundayo, 8% of participants stopped early due to side effects. Direct comparison of the two pills Feature Wegovy (oral form) Foundayo (oral form) Average weight loss 13.6% – 14% (Higher efficacy) 11% – 12.4% Gastrointestinal side effects Very common (approx. 74%) Very common (60-69%) Discontinuation due to side effects 6.9% (Slightly fewer) 8% Administration requirements Must be taken on an empty stomach in the morning with at most a small glass of water. Thereafter, you must fast for 30 minutes. Can be taken at any time of day, with or without food and drink (Much more flexible). Summary: What should you choose? • Wegovy is best on the numbers, as it has yielded a slightly greater weight loss in clinical studies. • Foundayo is best on everyday comfort, because you avoid the strict morning fasting rules that the Wegovy pill requires. Note: While Wegovy is widely available, Foundayo (orforglipron) is approved in the US and UK, but is still awaiting final rollout on the Danish market following EU approval. If you are considering medical weight loss, I can help you look into it further. Are you primarily considering pills, or is the Wegovy injection (taken once a week) also an option for you? • Skanfeld Wegovy pill vs Foundayo — which GLP-1 pill? - Skanfeld Sep. 22, 2026 — The Wegovy pill gave on average slightly greater weight loss than Foundayo — and was close to the Wegovy injection. The figures come from various stu... • Pharmica Foundayo vs Wegovy Pill: Dosing and Side Effects Compared Active Ingredients: Foundayo (orforglipron, Eli Lilly); Wegovy pill (oral semaglutide, Novo Nordisk). Licensed Uses: Foundayo (wei... • Oxford Online Pharmacy Wegovy pill vs Foundayo pill (Orforglipron): Which GLP-1 weight loss pill is better? Wegovy pill: Semaglutide, 13-16% body weight loss, strict fasting morning administration required, 4 step-up doses. Foundayo: Orfo... Show all This is for informational purposes only.
- ·6.10.I uploaded a video about how Eli Lilly dominates so much, and how they have a broad approach to the obesity market + that they are much more than just the obesity company many think they are: Eli Lilly (LLY): The Company That Beat Novo Nordisk (NVO https://youtu.be/HFBz-zoLH5M (Not advice, just my opinion)
- ·1.10.1 Major Novo competitor rejects disappointment Novo's major competitor Eli Lilly rejects disappointment over the weight loss pill Foundayo. This is reported by Finans based on an interview with the chief commercial officer at Eli Lilly, American Kenneth Custer. Sales amounted to 98 million dollars in the second quarter, but that was quite a bit less than investors had hoped for. Kenneth Custer points out that the company already has one third new pill patients with a brand that is only five months old, and which no one knew beforehand. He therefore rejects that Eli Lilly should be disappointed. maybe the downturn is coming now : )))))
- 29.9.Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison. https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more
- 29.9.Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-lossAnd even more side effects incl deaths, that is then mentioned in other financial media🤷♂️
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt